A retrospective study of 5-year outcomes of radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma refractory to Helicobacter pylori eradication therapy

Japanese Journal of Clinical Oncology

Volumn 43, Issue 9, 2013, Pages 917-922

  Abe, Seiichiro ^a   Oda, Ichiro ^a   Inaba, Koji ^a   Suzuki, Haruhisa ^a   Yoshinaga, Shigetaka ^a   Nonaka, Satoru ^a   Morota, Madoka ^a   Murakami, Naoya ^a   Itami, Jun ^a   Kobayashi, Yukio ^a   Maeshima, Akiko Miyagi ^a   Saito, Yutaka ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Helicobacter pylori; Long term outcomes; Mucosa associated lymphoid tissue lymphoma; Radiotherapy; Stomach

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE SPECIFIC SURVIVAL; ERADICATION THERAPY; FEMALE; FOLLOW UP; GASTRECTOMY; HELICOBACTER PYLORI; HEMATEMESIS; HUMAN; INTESTINE OBSTRUCTION; LUNG METASTASIS; MALE; MARGINAL ZONE LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RADIATION DOSE; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

HELICOBACTER PYLORI; LONG-TERM OUTCOMES; MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA; RADIOTHERAPY; STOMACH;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INTESTINAL NEOPLASMS; INTESTINAL OBSTRUCTION; LUNG NEOPLASMS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883310940     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt097     Document Type: Article

References (39)

1. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-49.
2. Andriani A, Miedico A, Tedeschi L, et al. Management and long-term follow-up of early stage H. pylori-associated gastric MALT-lymphoma in clinical practice: an Italian, multicentre study. Dig Liver Dis 2009;41:467-73.
3. Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut 2004;53:34-7.
4. Hong SS, Jung HY, Choi KD, et al. A prospective analysis of low-grade gastric malt lymphoma after Helicobacter pylori eradication. Helicobacter 2006;11:569-73.
5. Kim JS, Chung SJ, Choi YS, et al. Helicobacter pylori eradication for low-grade gastric mucosa-associated lymphoid tissue lymphoma is more successful in inducing remission in distal compared to proximal disease. Br J Cancer 2007;96:1324-28.
6. Nakamura S, Matsumoto T, Suekane H, et al. Long-term clinical outcome of Helicobacter pylori eradication for gastric mucosa-associated lymphoid tissue lymphoma with a reference to second-line treatment. Cancer 2005;104:532-40.
7. Terai S, Iijima K, Kato K, et al. Long-term outcomes of gastric mucosa-associated lymphoid tissue lymphomas after Helicobacter pylori eradication therapy. Tohoku J Exp Med 2008;214:79-87.
8. Wündisch T, Thiede C, Morgner A, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005;23:8018-24.
9. Zullo A, Hassan C, Cristofari F, et al. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol 2010;8:105-10.
10. Ono S, Kato M, Takagi K, et al. Long-term treatment of localized gastric marginal zone B-cell mucosa associated lymphoid tissue lymphoma including incidence of metachronous gastric cancer. J Gastroenterol Hepatol 2010;25:804-9.
11. Nakamura S, Sugiyama T, Matsumoto T, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut 2012;61:507-13.
12. Ruskoné-Fourmestraux A, Fischbach W, Aleman BM, et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011;60:747-58.
13. Tomita N, Kodaira T, Tachibana H, Nakamura T, Mizoguchi N, Takada A. Radiother Oncol 2009;90:231-5.
14. Vrieling C, de Jong D, Boot H, de Boer JP, Wegman F, Aleman BM. Long-term results of stomach-conserving therapy in gastric MALT lymphoma. Radiother Oncol 2008;87:405-11.
15. Yamashita H, Nakagawa K, Asari T, Murakami N, Igaki H, Ohtomo K. Radiotherapy for 41 patients with stages I and II MALT lymphoma: a retrospective study. Radiother Oncol 2008;87:412-17.
16. Sugimoto M, Kajimura M, Shirai N, et al. Outcome of radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma refractory to Helicobacter pylori eradication therapy. Intern Med 2006;45:405-9.
17. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003;21:4157-64.
18. Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 1998;16:1916-21.
19. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys 2001;50:1258-64.
20. Gobbi PG, Corbella F, Valentino F, et al. Complete long-term response to radiotherapy of gastric early-stage marginal zone lymphoma resistant to both anti-Helicobacter pylori antibiotics and chemotherapy. Ann Oncol 2009;20:465-68.
21. Goda JS, Gospodarowicz M, Pintilie M, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer 2010;116:3815-24.
22. Okada H, Takemoto M, Kawahara Y, et al. A prospective analysis of efficacy and long-term outcome of radiation therapy for gastric mucosa-associated lymphoid tissue lymphoma. Digestion 2012;86: 179-86.
23. Rohatiner A, d'Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 1994;5:397-400.
24. Nakamura S, Matsumoto T, Iida M, Yao T, Tsuneyoshi M. Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer 2003;97: 2462-73.
25. Kobayashi Y, Nakata M, Maekawa M, et al. Detection of t(11;18) in MALT-type lymphoma with dual-color fluorescence in situ hybridization and reverse transcriptase-polymerase chain reaction. Diagn Mol Pathol 2001;10:207-13.
26. Copie-Bergman C, Gaulard P, Lavergne-Slove A, et al. Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma. Gut 2003;52:1655-58.
27. National Cancer Institute [Internet]. Bethesda: Common Terminology Criteria for Adverse Events v4.0 [updated 2013 Mar 20; cited 2010 Mar 11]. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40.
28. Raderer M, Vorbeck F, Formanek M, et al. Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma. Br J Cancer 2000;83:454-57.
29. Park HS, Kim YJ, Yang WI, Suh CO, Lee YC. Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma. World J Gastroenterol 2010;16:2158-62.
30. Koch P, Probst A, Berdel WE, et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GITNHL 02/96). J Clin Oncol 2005;23:7050-59.
31. Kuo SH, Chen LT, Wu MS, et al. Long-term follow-up of gastrectomized patients with mucosa-associated lymphoid tissue lymphoma: need for a revisit of surgical treatment. Ann Surg 2008;247:265-69.
32. Raderer M, Streubel B, Woehrer S, et al. High relapse rate in patients with MALT lymphoma warrants lifelong follow up. Clin Cancer Res 2005;11:3349-52.
33. Gobbi PG, Ghirardelli ML, Cavalli C, et al. The role of surgery in the treatment of gastrointestinal lymphomas other than low-grade MALT. Haematologica 2000;85:372-80.
34. Thieblemont C, Dumontet C, Bouafia F, et al. Outcome in relation to treatment modalities in 48 patients with localized gastric MALT lymphoma: a retrospective study of patients treated during 1976-2001. Leuk Lymphoma 2003;44:257-62.
35. Mafune KI, Tanaka Y, Suda Y, Izumo T. Outcome of patients with non-Hodgkin's lymphoma of the stomach after gastrectomy: clinicopathologic study and reclassification according to the revised European-American lymphoma classification. Gastric Cancer 2001;4:137-43.
36. Fischbach W, Goebeler ME, Ruskone-Fourmestraux A, et al. Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series. Gut 2007;56:1685-57.
37. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003;21:897-906.
38. Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British Cohort: the relation to age at treatment. J Clin Oncol 2000;18:498-509.
39. Nakamura T, Seto M, Tajika M, et al. Clinical features and prognosis of gastric MALT lymphoma with special reference to responsiveness to H. pylori eradication and API2-MALT1 status. Am J Gastroenterol 2008;103:62-70.